Trends in oral cavity, pharyngeal, oesophageal and gastric cancer mortality rates in Spain, 1952–2006: an age-period-cohort analysis

BMC Cancer

Daniel Seoane-Mato¹  Nuria Aragonés²  Eva Ferreras²  Javier García-Pérez²  Marta Cervantes-Amat²  Pablo Fernández-Navarro²  Roberto Pastor-Barriuso²  Gonzalo López-Abente² 

[1] Cancer and Environmental Epidemiology Area, National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain

[2] CIBER in Epidemiology and Public Health (CIBERESP), Madrid, Spain

关键词: Spain;    Time trends;    Change-points;    Age-cohort-period analysis;    Mortality;    Gastric cancer;    Oesophageal cancer;    Oral and pharyngeal cancer;   

Others  :  858903
DOI  :  10.1186/1471-2407-14-254

 received in 2013-11-27, accepted in 2014-04-08,  发布年份 2014

【 摘 要 】

Background

Although oral cavity, pharyngeal, oesophageal and gastric cancers share some risk factors, no comparative analysis of mortality rate trends in these illnesses has been undertaken in Spain. This study aimed to evaluate the independent effects of age, death period and birth cohort on the mortality rates of these tumours.

Methods

Specific and age-adjusted mortality rates by tumour and sex were analysed. Age-period-cohort log-linear models were fitted separately for each tumour and sex, and segmented regression models were used to detect changes in period- and cohort-effect curvatures.

Results

Among men, the period-effect curvatures for oral cavity/pharyngeal and oesophageal cancers displayed a mortality trend that rose until 1995 and then declined. Among women, oral cavity/pharyngeal cancer mortality increased throughout the study period whereas oesophageal cancer mortality decreased after 1970. Stomach cancer mortality decreased in both sexes from 1965 onwards. Lastly, the cohort-effect curvature showed a certain degree of similarity for all three tumours in both sexes, which was greater among oral cavity, pharyngeal and oesophageal cancers, with a change point in evidence, after which risk of death increased in cohorts born from the 1910-1920s onwards and decreased among the 1950–1960 cohorts and successive generations. This latter feature was likewise observed for stomach cancer.

Conclusions

While the similarities of the cohort effects in oral cavity/pharyngeal, oesophageal and gastric tumours support the implication of shared risk factors, the more marked changes in cohort-effect curvature for oral cavity/pharyngeal and oesophageal cancer could be due to the greater influence of some risk factors in their aetiology, such as smoking and alcohol consumption. The increase in oral cavity/pharyngeal cancer mortality in women deserves further study.

【 授权许可】

   
2014 Seoane-Mato et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM: Globocan 2008: Cancer Incidence and Mortality Worldwide. IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer; 2010.
• [2]Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, Capocaccia R: EUROCARE-4. Survival of cancer patients diagnosed in 1995–1999. Results and commentary. Eur J Cancer 2009, 45:931-991.
• [3]Zigon G, Berrino F, Gatta G, Sánchez M-J, van Dijk B, Van Eycken E, Francisci S: Prognoses for head and neck cancers in Europe diagnosed in 1995–1999: a population-based study. Ann Oncol 2011, 22:165-174.
• [4]De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, Trama A, Visser O, Brenner H, Ardanaz E, Bielska-Lasota M, Engholm G, Nennecke A, Siesling S, Berrino F, Capocaccia R: EUROCARE-5 Working Group: Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE–5-a population-based study. Lancet Oncol 2014, 15:23-34.
• [5]National Center for Epidemiology: Mortalidad por Cáncer en España (2010) [Cancer Mortality in Spain (2010)]. 2011. http://www.isciii.es/ISCIII/es/contenidos/fd-servicios-cientifico-tecnicos/fd-vigilancias-alertas/fd-epidemiologia-ambiental-y-cancer/mortalidad-cancer-en-espana.shtml webcite (accessed 15 September 2013)
• [6]Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, Forman D, Bray F: Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer 2013, 49:1374-1403.
• [7]Smith EM, Rubenstein LM, Haugen TH, Pawlita M, Turek LP: Complex etiology underlies risk and survival in head and neck cancer human papillomavirus, tobacco, and alcohol: a case for multifactor disease. J Oncol 2012, 2012:571862.
• [8]D’Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, Westra WH, Gillison ML: Case–control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007, 356:1944-1956.
• [9]Pennathur A, Gibson MK, Jobe BA, Luketich JD: Oesophageal carcinoma. Lancet 2013, 381:400-412.
• [10]González CA, Agudo A: Carcinogenesis, prevention and early detection of gastric cancer: where we are and where we should go. Int J Cancer 2012, 130:745-753.
• [11]La Vecchia C, Tavani A, Franceschi S, Levi F, Corrao G, Negri E: Epidemiology and prevention of oral cancer. Oral Oncol 1997, 33:302-312.
• [12]Levi F, Lucchini F, Negri E, Boyle P, La Vecchia C: Cancer mortality in Europe, 1990–1994, and an overview of trends from 1955 to 1994. Eur J Cancer 1999, 35:1477-1516.
• [13]Macfarlane GJ, Boyle P, Evstifeeva TV, Robertson C, Scully C: Rising trends of oral cancer mortality among males worldwide: the return of an old public health problem. Canc Causes Contr 1994, 5:259-265.
• [14]La Vecchia C, Lucchini F, Negri E, Levi F: Trends in oral cancer mortality in Europe. Oral Oncol 2004, 40:433-439.
• [15]Garavello W, Bertuccio P, Levi F, Lucchini F, Bosetti C, Malvezzi M, Negri E, La Vecchia C: The oral cancer epidemic in central and eastern Europe. Int J Cancer 2010, 127:160-171.
• [16]Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, Jiang B, Goodman MT, Sibug-Saber M, Cozen W, Liu L, Lynch CF, Wentzensen N, Jordan RC, Altekruse S, Anderson WF, Rosenberg PS, Gillison ML: Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011, 29:4294-4301.
• [17]Bosetti C, Levi F, Ferlay J, Garavello W, Lucchini F, Bertuccio P, Negri E, La Vecchia C: Trends in oesophageal cancer incidence and mortality in Europe. Int J Cancer 2008, 122:1118-1129.
• [18]Aragonés N, Pollán M, Rodero I, López-Abente G: Gastric cancer in the European Union (1968–1992): mortality trends and cohort effect. Ann Epidemiol 1997, 7:294-303.
• [19]Bosetti C, Bertuccio P, Malvezzi M, Levi F, Chatenoud L, Negri E, La Vecchia C: Cancer mortality in Europe, 2005–2009, and an overview of trends since 1980. Ann Oncol 2013, 24:2657-2671.
• [20]Osmond C, Gardner MJ: Age, period and cohort models applied to cancer mortality rates. Stat Med 1982, 1:245-259.
• [21]Holford TR: Understanding the effects of age, period, and cohort on incidence and mortality rates. Annu Rev Public Health 1991, 12:425-457.
• [22]Breslow NE: Extra-Poisson variation in Log-linear models. Appl Stat 1984, 33:38-44.
• [23]Muggeo VM: Estimating regression models with unknown break-points. Stat Med 2003, 22:3055-3071.
• [24]Muggeo VM: Segmented: segmented relationships in regression models. R package version 0.1-4. 2004.
• [25]Regidor E, Gutiérrez-Fisac JL, De Los Santos Ichaso M, Fernández E: Trends in principal cancer risk factors in Spain. Ann Oncol 2010, 21(3):iii37-iii42.
• [26]Aragonés N, Goicoa T, Pollán M, Militino AF, Pérez-Gómez B, López-Abente G, Ugarte MD: Spatio-temporal trends in gastric cancer mortality in Spain: 1975–2008. Canc Epidemiol 2013, 37:360-369.
• [27]Hashibe M, Brennan P, Chuang S-C, Boccia S, Castellsague X, Chen C, Curado MP, Dal Maso L, Daudt AW, Fabianova E, Fernandez L, Wünsch-Filho V, Franceschi S, Hayes RB, Herrero R, Kelsey K, Koifman S, La Vecchia C, Lazarus P, Levi F, Lence JJ, Mates D, Matos E, Menezes A, McClean MD, Muscat J, Eluf-Neto J, Olshan AF, Purdue M, Rudnai P, et al.: Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev 2009, 18:541-550.
• [28]Anantharaman D, Marron M, Lagiou P, Samoli E, Ahrens W, Pohlabeln H, Slamova A, Schejbalova M, Merletti F, Richiardi L, Kjaerheim K, Castellsague X, Agudo A, Talamini R, Barzan L, Macfarlane TV, Tickle M, Simonato L, Canova C, Conway DI, McKinney PA, Thomson P, Znaor A, Healy CM, McCartan BE, Hashibe M, Brennan P, Macfarlane GJ: Population attributable risk of tobacco and alcohol for upper aerodigestive tract cancer. Oral Oncol 2011, 47:725-731.
• [29]Correa P, Houghton J: Carcinogenesis of Helicobacter pylori. Gastroenterology 2007, 133:659-672.
• [30]González CA, López-Carrillo L: Helicobacter pylori, nutrition and smoking interactions: their impact in gastric carcinogenesis. Scand J Gastroenterol 2010, 45:6-14.
• [31]Marur S, D’Souza G, Westra WH, Forastiere AA: HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 2010, 11:781-789.
• [32]Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, Forastiere A, Gillison ML: Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008, 100:261-269.
• [33]Fakhry C, Gillison ML: Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol 2006, 24:2606-2611.
• [34]Hammarstedt L, Lindquist D, Dahlstrand H, Romanitan M, Dahlgren LO, Joneberg J, Creson N, Lindholm J, Ye W, Dalianis T, Munck-Wikland E: Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer. Int J Cancer 2006, 119:2620-2623.
• [35]Attner P, Du J, Näsman A, Hammarstedt L, Ramqvist T, Lindholm J, Marklund L, Dalianis T, Munck-Wikland E: The role of human papillomavirus in the increased incidence of base of tongue cancer. Int J Cancer 2010, 126:2879-2884.
• [36]Näsman A, Attner P, Hammarstedt L, Du J, Eriksson M, Giraud G, Ahrlund-Richter S, Marklund L, Romanitan M, Lindquist D, Ramqvist T, Lindholm J, Sparén P, Ye W, Dahlstrand H, Munck-Wikland E, Dalianis T: Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer 2009, 125:362-366.
• [37]International Agency for Research on Cancer: Human Papillomaviruses. IARC Monographs Volume 90. Lyon, France: IARC; 2007.
• [38]International Agency for Research on Cancer: A Review of Human Carcinogens: Biological Agents. IARC Monographs Volume 100 - Part B. Lyon, France: IARC; 2012.
• [39]Anantharaman D, Gheit T, Waterboer T, Abedi-Ardekani B, Carreira C, McKay-Chopin S, Gaborieau V, Marron M, Lagiou P, Ahrens W, Holcátová I, Merletti F, Kjaerheim K, Talamini R, Simonato L, Castellsague X, Macfarlane TV, Biggs A-M, Thakker N, Znaor A, Thomson P, Canova C, Conway DI, Healy CM, Tommasino M, Pawlita M, Brennan P: Human Papillomavirus Infections and Upper Aero-Digestive Tract Cancers: The ARCAGE Study. J Natl Cancer Inst 2013, 105:536-545.
• [40]Veldhuijzen NJ, Snijders PJ, Reiss P, Meijer CJ, van de Wijgert JH: Factors affecting transmission of mucosal human papillomavirus. Lancet Infect Dis 2010, 10:862-874.
• [41]Bosch FX, Lorincz A, Muñoz N, Meijer CJLM, Shah KV: The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002, 55:244-265.
• [42]Gillison ML, Broutian T, Pickard RKL, Tong Z, Xiao W, Kahle L, Graubard BI, Chaturvedi AK: Prevalence of oral HPV infection in the United States, 2009–2010. JAMA 2012, 307:693-703.
• [43]Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S: Cervical human papillomavirus prevalence in 5 continents: meta‒analysis of 1 million women with normal cytological findings. J Infect Dis 2010, 202:1789-1799.
• [44]Kreimer AR, Bhatia RK, Messeguer AL, González P, Herrero R, Giuliano AR: Oral human papillomavirus in healthy individuals: a systematic review of the literature. Sex Transm Dis 2010, 37:386-391.
• [45]De Sanjose S, Almirall R, Lloveras B, Font R, Diaz M, Muñoz N, Català I, Meijer CJLM, Snijders PJF, Herrero R, Bosch FX: Cervical human papillomavirus infection in the female population in Barcelona, Spain. Sex Transm Dis 2003, 30:788-793.
• [46]De Vuyst H, Clifford G, Li N, Franceschi S: HPV infection in Europe. Eur J Cancer 2009, 45:2632-2639.
• [47]De Sanjose S, Cortés X, Méndez C, Puig-Tintore L, Torné A, Roura E, Bosch FX, Castellsague X: Age at sexual initiation and number of sexual partners in the female Spanish population. Eur J Obstet Gynecol Reprod Biol 2008, 140:234-240.
• [48]Zandberg DP, Bhargava R, Badin S, Cullen KJ: The role of human papillomavirus in nongenital cancers. CA Cancer J Clin 2013, 63:57-81.
• [49]Aragonés N, Izarzugaza MI, Ramos M, Chirlaque MD, Almar E, Martínez C: Trends in oesophago-gastric cancer incidence in Spain: analysis by subsite and histology. Ann Oncol 2010, 21(3):iii69-iii75.
• [50]Sitas F, Egger S, Urban MI, Taylor PR, Abnet CC, Boffetta P, O’Connell DL, Whiteman DC, Brennan P, Malekzadeh R, Pawlita M, Dawsey SM, Waterboer T, on behalf of the InterSCOPE Collaboration: InterSCOPE study: associations between esophageal squamous cell carcinoma and human papillomavirus serological markers. J Natl Cancer Inst 2012, 104:147-158.
• [51]Brown LM: Helicobacter pylori: epidemiology and routes of transmission. Epidemiol Rev 2000, 22:283-297.
• [52]Pérez-Gómez B, Aragonés N, Pollán M, Suárez B, Lope V, Llácer A, López-Abente G: Accuracy of cancer death certificates in Spain: a summary of available information. Gac Sanit 2006, 20(Suppl 3):42-51.
• [53]Grupo de trabajo de la Ponencia y Registro de Vacunaciones: Virus del Papiloma Humano. Situación Actual, Vacunas y Perspectivas de su Utilización. Madrid: Ministerio de Sanidad y Consumo; 2007.